These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32601387)

  • 1. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
    Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
    Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
    Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
    J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
    Gross AM; Dombi E; Widemann BC
    Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
    Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
    Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
    Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
    Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
    Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
    Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
    Mazuelas H; Carrió M; Serra E
    Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.
    Kraniak JM; Chalasani A; Wallace MR; Mattingly RR
    Exp Neurol; 2018 Jan; 299(Pt B):289-298. PubMed ID: 29055717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
    Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
    Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.
    Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Raghunathan A; Schwartz J; Spinner RJ
    J Neurooncol; 2024 Aug; 169(1):147-153. PubMed ID: 38739187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
    Veres K; Bene J; Hadzsiev K; Garami M; Pálla S; Happle R; Medvecz M; Szalai ZZ
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.
    Church C; Fay CX; Kriukov E; Liu H; Cannon A; Baldwin LA; Crossman DK; Korf B; Wallace MR; Gross AM; Widemann BC; Kesterson RA; Baranov P; Wallis D
    Acta Neuropathol Commun; 2024 Jun; 12(1):102. PubMed ID: 38907342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.